These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 6879640)

  • 1. The aminoglycoside panel: a new approach to monitoring aminoglycoside therapy.
    Gorsky JE; Latts JR
    Ther Drug Monit; 1983 Jun; 5(2):169-72. PubMed ID: 6879640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum aminoglycoside monitoring by enzyme immunoassay, biological, and fluorescence immunoassay procedures.
    Buchanan AG; Witwicki E; Albritton WL
    Am J Med Technol; 1983 Jun; 49(6):437-41. PubMed ID: 6349357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of serum concentrations of some aminoglycoside antibiotics by use of the fluorescent immunoassay method.
    Dzierzanowska D; Nowik-Jurek M; Podleśny J
    Arch Immunol Ther Exp (Warsz); 1983; 31(3):389-94. PubMed ID: 6651487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients.
    Mann HJ; Wittbrodt ET; Baghaie AA; Cerra FB
    Pharmacotherapy; 1998; 18(2):371-8. PubMed ID: 9545157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective audit of an aminoglycoside consultative service in a general hospital.
    Li SC; Ioannides-Demos LL; Spicer WJ; Spelman DW; Tong N; McLean AJ
    Med J Aust; 1992 Sep; 157(5):308-11. PubMed ID: 1435470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining aminoglycoside dosage and blood levels using a programmable calculator.
    Ng PK
    Am J Hosp Pharm; 1980 Feb; 37(2):225-31. PubMed ID: 7361795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglycoside monitoring program.
    Vakoutis J; Stein GE; Miller PB; Clayman AE
    Am J Hosp Pharm; 1981 Oct; 38(10):1477-80. PubMed ID: 7294041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.
    de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN
    Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic monitoring as an aid in rationalizing aminoglycoside dosage techniques in the neonate.
    Spruyt LL; Kirsten GF; Parkin DP; Müller GJ; Kriegler A
    S Afr Med J; 1987 Oct; 72(7):463-5. PubMed ID: 3660149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit.
    Ohler KH; Menke JA; Fuller L
    Am J Perinatol; 2000; 17(6):285-90. PubMed ID: 11144309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group.
    Dorman T; Swoboda S; Zarfeshenfard F; Trentler B; Lipsett PA
    Surgery; 1998 Jul; 124(1):73-8. PubMed ID: 9663254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of time and temperature on inactivation of aminoglycosides by ampicillin at neonatal dosages.
    Daly JS; Dodge RA; Glew RH; Keroack MA; Bednarek FJ; Whalen M
    J Perinatol; 1997; 17(1):42-5. PubMed ID: 9069064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-benefit analysis of an aminoglycoside monitoring service.
    Kimelblatt BJ; Bradbury K; Chodoff L; Aggour T; Mehl B
    Am J Hosp Pharm; 1986 May; 43(5):1205-9. PubMed ID: 3087162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs.
    Prescott WA
    Respir Care; 2014 Sep; 59(9):1353-9. PubMed ID: 24782555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients.
    Prins JM; Weverling GJ; van Ketel RJ; Speelman P
    Clin Pharmacol Ther; 1997 Jul; 62(1):106-11. PubMed ID: 9246024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbenicillin inactivation of aminoglycosides in patients with severe renal failure.
    Weibert R; Keane W; Shapiro F
    Trans Am Soc Artif Intern Organs; 1976; 22():439-43. PubMed ID: 951863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishing an aminoglycoside pharmacokinetic monitoring service in a community hospital.
    Bollish SJ; Kelly WN; Miller DE; Timmons RG
    Am J Hosp Pharm; 1981 Jan; 38(1):73-6. PubMed ID: 7211873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.